Do I Qualify for GLP-1? An Honest Eligibility Quiz (October 2026)

01 · The quiz

The GLP-1 eligibility quiz: answer these questions honestly

Answer yes or no to each question below. Together they mirror what a prescriber looks at, using the licensed criteria for Mounjaro (tirzepatide), which is licensed for weight management in adults.¹

If you land in the eligible rows and none of the exclusion rows, a consultation is a sensible next step. It must sit alongside a reduced-calorie diet and increased physical activity, not replace them.¹

02 · Your result

How to read your result

If you answered yes to the BMI questions and no to the exclusion questions, you probably meet the licensed criteria. That does not mean you will be prescribed anything. A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹

If you are borderline, for example a BMI just under a threshold, do not try to adjust your figures to pass. Honest answers protect you, because the prescriber needs your real history to judge safety. Our guides on how you qualify for GLP-1 and knowing whether you qualify go into more detail on the borderline cases.

Ready to see whether you are suitable? Our free consultation is reviewed by a GPhC-registered prescriber, not a scoring script, and unsuitable orders are refunded automatically. You can start from the Mounjaro pen page.

Related guides: Glp 1 kvapky uzivanie and Glp 1 agonis.

03 · Licensed criteria explained

What the licensed criteria actually say

The licensed criteria are the only solid yardstick for a GLP-1 eligibility quiz in the UK. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.¹ It must be used alongside a reduced-calorie diet and increased physical activity.¹

Notice what the wording does and does not say. It sets a floor for who may be prescribed the medicine. It does not say everyone above that floor should take it, and it does not promise a prescription. The final sentence of the criteria matters most: a prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹

That is why the quiz format has limits. A score from a web page cannot see your medicine list, cannot ask follow-up questions about an old gallbladder problem, and cannot weigh a family history of thyroid cancer. Many online quizzes also ask for your details first and give a result that is really a sales funnel.

You may see other sites quote a different set of rules. The outline most people encounter, a BMI of 30 or more, or 27 or more with a related condition, matches the licence for weight management. Rules for diabetes treatment are separate: tirzepatide is also licensed for type 2 diabetes, and your diabetes team manages that route.¹

Terms are worth getting straight. GLP-1 is the name of a natural gut hormone, and medicines that act on its receptor are called GLP-1 receptor agonists.

In practice, the sequence is simple. You describe your height, weight, health conditions and medicines. A clinician checks them against the licensed criteria and the safety information in the product literature. If everything lines up, treatment can start at the lowest dose. If it does not, you should hear why, and an order we cannot approve is refunded automatically in full.

A final point on honesty: the criteria are a licence, not a medical judgement about your worth or willpower. Obesity is a medical condition with many causes, and being eligible simply means the medicine has been tested and approved for people in your position.

04 · BMI and your numbers

Working out your BMI and why it matters

BMI is your weight in kilograms divided by your height in metres squared, expressed in kg/m². It is the first number any GLP-1 eligibility quiz asks for, because the licence is built around it.¹ The thresholds that matter are 27, 30, 35 and 40, and each one has a job.

A BMI of 30 or above meets the main private-prescribing criterion, with no extra condition needed. A BMI from 27 up to 30 qualifies only when there is at least one weight-related condition on top. The higher thresholds, 35 and 40, are not private-prescribing hurdles. They matter mainly for NHS access.

Be realistic about what BMI can and cannot tell you. It is a screening number. It does not separate muscle from fat, it does not show where fat is carried, and it says nothing about your blood pressure, sleep or blood sugar. That is exactly why a prescriber also looks at your medical history rather than treating BMI as a pass or fail mark.

Accuracy matters because the number should be measured, not guessed. Weigh yourself in the morning, on the same scales, wearing light clothing, and measure your height without shoes. If you are close to a threshold, a small error can flip your result, and the prescriber will want figures you can stand behind. Do not round up to qualify. If a prescriber cannot rely on your answers, they cannot safely prescribe for you.

If your BMI is only slightly under a threshold, two things are worth checking. First, whether a weight-related condition applies to you: many people have high blood pressure or high cholesterol that was picked up at a routine check without making them feel unwell. Second, whether an ethnic-background adjustment applies.

If your BMI is clearly below the licensed range and you have no qualifying condition, treatment is not an appropriate route. Sustainable changes to eating and activity, with support from your GP or a weight-management service, are the better path. Our weight loss clinic page explains the options we offer for people who are eligible.

Finally, remember that BMI is only checked at the start. During treatment, the prescribing team carries out monthly reviews and follow-up assessments, and repeat orders re-check suitability. There is no auto-shipping, so your eligibility is reviewed again over time, not only at your first consultation.

05 · Ethnicity and conditions

Ethnic background, weight-related conditions and borderline cases

Your ethnic background can change where you stand on the BMI scale. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight- related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups.¹ If that describes you, a quiz that applies only the standard thresholds may under-state your eligibility, and you should say so in your consultation.

Weight-related conditions are the other lever. The licence names high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes.¹ For someone with a BMI between 27 and 30, having one of these is what turns an ineligible result into an eligible one. Many people are surprised by how often these conditions go unnoticed. Snoring with daytime tiredness, for example, may point to sleep apnoea, which only a proper assessment can confirm.

What counts as evidence? A prescriber will typically want to know about diagnoses you have been given, medicines you take for them, and relevant test results. Be ready to share your medicine list, because current medicines are part of the assessment too.¹ Insulin or sulfonylureas, for instance, are worth flagging because doses may need adjusting when taking this medicine, to avoid low blood sugar.

Contraception deserves a mention. Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ That is a conversation to have with the prescriber, not a reason to stop reading, and it is another reason a quiz cannot replace a consultation.

Borderline cases are common, and here is how to think about them. If you sit just under a BMI of 30 and have a qualifying condition, you may still be eligible. If you sit just under 27, the licence does not stretch. If you are in an ethnic group with reduced thresholds, apply the adjustment before you decide. In every case, the quiz is only the opening question. The real decision follows a review of your history.

Do not self-diagnose conditions to pass. If you suspect you have high blood pressure or high cholesterol but have never been tested, a GP check or a pharmacy test is a better first step than a weight-loss consultation. Treating the underlying condition properly is worth doing whatever you decide about medication.

06 · Who cannot take it

What disqualifies you from taking GLP-1 treatment

A few things rule treatment out outright, and a few more call for caution. Mounjaro is not suitable for everyone. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive.¹ Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly.

Then come the situations where a prescriber takes extra care or may recommend against treatment: a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems.¹ None of these is an automatic bar in every case, which is exactly why the decision cannot be made by a web form. Severity, timing and your other medicines all matter, and only a clinician can weigh them.

Thyroid safety gets its own mention because it features in nearly every discussion of GLP-1 medicines. In rodent studies tirzepatide caused thyroid C-cell tumours. It is not known whether this applies to humans, and no increase has been shown in human trials.¹ As a precaution, tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2, because they will weigh this in your assessment. Routine thyroid monitoring is not required for most people.¹

The questions in our consultation exist because the answers change what is safe. Always share your full medical history and medicine list during consultation.¹ Leaving something out because it seems minor is the most common way people end up with unsuitable treatment.

What about side effects? Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. Your prescriber will go through the other known side effects with you.¹³ If you notice a new symptom while on treatment, speak to your prescriber, and you can report suspected side effects through the MHRA Yellow Card scheme.¹⁹

If you answered yes to any exclusion in the quiz, the sensible step is not to give up, but to put it in front of a clinician. A prescriber may confirm treatment is unsuitable, and in that case an order is refunded automatically. Or they may find that your situation, for instance a gallbladder problem long resolved, can be managed with caution. What you should not do is buy from anyone offering to supply without a consultation or prescription, because that removes the safety check the exclusions exist for.

A last practical point: eligibility is not permanent. A pregnancy plan, a new diagnosis, or a change in medicines can alter suitability, so tell the prescribing team about changes at your monthly review.

07 · NHS or private?

NHS or private: which route might apply to you?

The NHS and private routes use different thresholds, so passing one quiz does not mean passing both. Mounjaro is available on the NHS, but access is being phased in over several years.⁶ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁶

Put simply, the NHS focuses first on those with the greatest health need, so the BMI bar is higher. The private route follows the licence, which starts lower. Someone with a BMI of 32 and no conditions would not be in an early NHS group but could meet the licensed criteria privately, subject to a prescriber's review.

If you think you may qualify on the NHS, your GP is the right place to ask. NHS access to Wegovy runs through specialist weight-management services; ask your GP. The NHS pages on tirzepatide explain the current position in more detail.⁵

How does the cost picture look if you go private? The honest answer is that it depends on the dose you settle on. Our starting pen costs £169.99 at standard price, and a new customer saves £40 on their first order with code FIRST40. An automatic £25 reorder discount applies to every future order (code DOSE25). If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices; a new customer's first order is £40 less and every later order £25 less. A first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg. Prices checked 10 October 2026.

These are real sums, so it is reasonable to compare routes. You can wait for NHS access if you are in a group that is being prioritised, or you can start privately now if you meet the licensed criteria. Some people do both: begin privately, and move over if and when NHS provision reaches them. Whatever you choose, make sure the pharmacy is registered. Ours is GPhC-registered, number 9012878, and you can check any pharmacy on the public register.¹²

Pay-monthly options and Klarna are available, with no subscription lock-in, so you only order when you choose to. Consultation is free, and the price shown is the price paid with no hidden fees.

The takeaway for the quiz: if your BMI is at or above 35 with a condition, speak to your GP about the NHS route as well. If your BMI is lower but within the licence, the private route is the one that currently fits.

08 · What results look like

Weight loss on GLP-1: what to expect once you qualify

Qualifying only matters if you know what treatment can realistically deliver. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

The trial also reported how many people reached particular milestones. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight.² Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.² As a worked example only, for someone starting at 100 kg, 20.9% is about 21 kg. Trial averages do not predict your own result.

How much can you lose in three months? Three months in, most people are still on the lower rungs of the dose ladder, so trial-average losses at this stage are modest compared with the headline figures: in SURMOUNT-1, average weight loss built month by month, with the full 15–21% averages measured at 72 weeks, not 12. A sensible 3-month expectation on a standard titration is mid single digits as a percentage of body weight, with wide individual variation. Slower early progress does not predict failure — the dose you respond to may still be ahead of you.

How does it work? Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

And when you stop? Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4–5 weeks to clear the system, there is no way to speed this up, and nothing needs doing while it clears.¹ Mounjaro manages weight; it does not cure the biology behind it. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.

Treat these figures as the upper end of what a trial population achieved under supervision, not a promise. Setting a realistic expectation is part of a good consultation.

09 · Choosing your medicine

Which GLP-1 medicine, and how to move from quiz to order

Eligibility is the first question; which medicine is the second. The main injectable options in the UK are Mounjaro (tirzepatide), Wegovy (semaglutide) and daily liraglutide. Mounjaro is a once-weekly injectable made by Eli Lilly, in a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic).¹

Wegovy pens are 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg once weekly, with titration stepping up after at least four weeks and reaching the 2.4mg maintenance dose from week 17.¹⁸ Liraglutide, as Saxenda or products such as Erly, is supplied at 6mg/ml and is a daily injection, unlike once-weekly Mounjaro and Wegovy. Your first Wegovy pen is a first-order price of £99.99, and you can see current details on the Wegovy pen page.

SURMOUNT-5 is the first large head-to-head trial of tirzepatide against semaglutide for weight loss.¹⁵ Both are licensed treatments, and the choice depends on your history and your prescriber's advice.

Once you know the medicine you want to consider, ordering is straightforward. First comes a free online consultation: a short health questionnaire, no charge, no obligation. Second, a GPhC-registered prescriber reviews it. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Third, our registered pharmacy dispenses it, with same-day dispatch when ordered by 3pm. Delivery is free next-day tracked (DPD, temperature-controlled packaging, discreet). Saturday delivery is £14.99.

Supply matters for safety. We source Mounjaro through official LillyDirect supply, direct from Eli Lilly's UK distribution, as genuine KwikPens, and all six doses are in stock. Counterfeit pens are a real risk when buying from unregulated sellers, so check the register and avoid anyone who will supply without a consultation or prescription.⁷

Store pens in the fridge at 2–8°C and never freeze them; once in use, a pen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away. Needles, a sharps bin and injection guidance are included with every order, and the prescribing team offers monthly reviews, dose titration and side-effect support. Our support team is on the phone Monday–Friday 9am–5pm. If you want to track your progress, the free GLPTrackr app is available on iOS and Android.

When you are ready, begin at the Mounjaro pen prices and consultation page. The pace is yours. Nothing auto-ships, and every repeat order re-checks that treatment is still suitable.

If you want to learn how adoption of these medicines has changed, our overview of GLP-1 adoption covers the background.